# A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

> **NCT04809467** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 54 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** tafasitamab
- **DRUG:** parsaclisib

## Key facts

- **NCT ID:** NCT04809467
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-16
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809467, "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04809467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*